Morgan Stanley maintains Ascendis Pharma at Overweight; cuts price target
Morgan Stanley maintained Ascendis Pharma at Overweight and cut its price target to $273.00 per share from $275.00, according to Benzinga/TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.